These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19847195)

  • 1. The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus.
    de Boer RA; Martens FM; Kuipers I; Boomsma F; Visseren FL
    J Hum Hypertens; 2010 Jan; 24(1):74-6. PubMed ID: 19847195
    [No Abstract]   [Full Text] [Related]  

  • 2. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 3. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.
    Zanchi A; Chiolero A; Maillard M; Nussberger J; Brunner HR; Burnier M
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1140-5. PubMed ID: 15001599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
    Consoli A; Formoso G
    Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.
    Nagashima K; Lopez C; Donovan D; Ngai C; Fontanez N; Bensadoun A; Fruchart-Najib J; Holleran S; Cohn JS; Ramakrishnan R; Ginsberg HN
    J Clin Invest; 2005 May; 115(5):1323-32. PubMed ID: 15841215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPAR-gamma: therapeutic target for ischemic stroke.
    Culman J; Zhao Y; Gohlke P; Herdegen T
    Trends Pharmacol Sci; 2007 May; 28(5):244-9. PubMed ID: 17416424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
    Krag MB; Nielsen S; Guo Z; Pedersen SB; Schmitz O; Christiansen JS; Jørgensen JO
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones in peritoneal dialysis patients.
    Szeto CC; Chow KM
    Perit Dial Int; 2009; 29(3):248-51. PubMed ID: 19458290
    [No Abstract]   [Full Text] [Related]  

  • 11. Pioglitazone.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 Mar; 65(3):333-5. PubMed ID: 26554102
    [No Abstract]   [Full Text] [Related]  

  • 12. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice.
    Huang PH; Sata M; Nishimatsu H; Sumi M; Hirata Y; Nagai R
    Biomed Pharmacother; 2008 Jan; 62(1):46-52. PubMed ID: 17692499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.
    Zafiriou S; Stanners SR; Saad S; Polhill TS; Poronnik P; Pollock CA
    J Am Soc Nephrol; 2005 Mar; 16(3):638-45. PubMed ID: 15689403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rosiglitazone on early-morning plasma cortisol levels.
    Catrina SB; Virtanen K; Hällsten K; Lönnqvist F; Nuutila P; Brismar K
    Neuro Endocrinol Lett; 2005 Dec; 26(6):763-4; author reply 765. PubMed ID: 16380670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone and bladder cancer.
    Ryder RE
    Lancet; 2011 Oct; 378(9802):1544; author reply 1544-5. PubMed ID: 22035551
    [No Abstract]   [Full Text] [Related]  

  • 16. Pioglitazone and bladder cancer.
    Hillaire-Buys D; Faillie JL; Montastruc JL
    Lancet; 2011 Oct; 378(9802):1543-4; author reply 1544-5. PubMed ID: 22035550
    [No Abstract]   [Full Text] [Related]  

  • 17. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
    Charbonnel B
    Lancet; 2009 Jul; 374(9684):96-8. PubMed ID: 19515412
    [No Abstract]   [Full Text] [Related]  

  • 18. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
    Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.
    Sato T; Hanyu H; Hirao K; Kanetaka H; Sakurai H; Iwamoto T
    Neurobiol Aging; 2011 Sep; 32(9):1626-33. PubMed ID: 19923038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between peroxisome proliferator-activated receptor-gamma activation and the ameliorative effects of ascochlorin derivatives on type II diabetes.
    Magae J; Tsuruga M; Maruyama A; Furukawa C; Kojima S; Shimizu H; Ando K
    J Antibiot (Tokyo); 2009 Jul; 62(7):365-9. PubMed ID: 19557028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.